Carbamazepine (Epilepsy)

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12854
R48478		 Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 Urinary malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.40 [0.04;3.68] C
excluded (control group) 		4/490   1/50 5 490
ref
S12855
R48488		 Thomas (Carbamazepine) (Controls unexposed, sick), 2021 Urinary malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 0.46 [0.13;1.64] C 4/490   6/340 10 490
ref
S382
R16398		 Tomson (Carbamazepine), 2018 Renal malformations at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.93 [0.79;4.74] C 12/1,957   8/2,514 20 1,957
ref
S302
R15857		 Artama (Carbamazepine), 2005 Urinary system 1st trimester retrospective cohort (registry) unexposed, sick Adjustment: No 2.34 [0.21;25.81] C 2/805   1/939 3 805
ref
Total 3 studies 1.19 [0.42;3.39] 33 3,252
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Carbamazepine) (Controls unexposed, sick), 2021Thomas, 2021 1 0.46[0.13; 1.64]1049036%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Tomson (Carbamazepine), 2018Tomson, 2018 2 1.93[0.79; 4.74]201,95749%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Artama (Carbamazepine), 2005Artama, 2005 3 2.34[0.21; 25.81]380515%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 44% 1.19[0.42; 3.39]333,2520.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.19[0.42; 3.39]333,25244%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Tomson (Carbamazepine), 2018 Artama (Carbamazepine), 2005 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.74[0.17; 3.19]131,29528%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Artama (Carbamazepine), 2005 2 exposed to other treatment, sickexposed to other treatment, sick 1.93[0.79; 4.74]201,957 -NATomson (Carbamazepine), 2018 1 Tags Adjustment   - No  - No 1.19[0.42; 3.39]333,25244%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Tomson (Carbamazepine), 2018 Artama (Carbamazepine), 2005 3 All studiesAll studies 1.19[0.42; 3.39]333,25244%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Tomson (Carbamazepine), 2018 Artama (Carbamazepine), 2005 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12854

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.74[0.17; 3.19]131,29528%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Artama (Carbamazepine), 2005 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.24[0.31; 4.95]252,44740%NAThomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Carbamazepine), 2018 20.510.01.0